Literature DB >> 20075739

Nodular regenerative hyperplasia of the liver: survival and associated features in a UK case series.

Jude M Morris1, Karin A Oien, Marie McMahon, Ewan H Forrest, John Morris, Adrian J Stanley, Stewart Campbell.   

Abstract

AIMS: Nodular regenerative hyperplasia (NRH) is a rarely identified liver disorder. It is characterized histologically by nodular hepatocyte regeneration without significant fibrosis, and clinically by portal hypertension and abnormal liver function tests (LFTs). Survival data in an unselected cohort after diagnosis of NRH have not been previously described. This study aims to identify a regional cohort with NRH, to determine survival after diagnosis and to assess the relative frequency of associated conditions.
METHODS: Patients were identified retrospectively from liver biopsy reports within pathology databases, over a 13-year period from Glasgow, Scotland, UK. Case notes were retrieved, clinical information extracted and survival was determined.
RESULTS: Forty-two patients were identified (19 males). Common presenting features were abnormal LFTs (predominantly cholestatic) (76%) and portal hypertension (9.5%). None had severe liver dysfunction (Child-Pugh score A: 81%, B: 19%, C: 0%). Varices were detected in 26%, and portal hypertension was detected in 31%. There were five (12%) variceal bleeds, one fatal. The patients were subdivided into four groups according to associated clinical conditions: malignancy (29%), prothrombotic (21%), rheumatological (24%) and idiopathic/other (26%). Mean survival was 8.1 years, although survival was highly variable, and was associated with age and associated disease, but not with portal hypertension or varices. No patients in the rheumatological subgroup died.
CONCLUSION: NRH is usually associated with malignant, prothrombotic or rheumatological conditions. Survival is highly variable and related to age and the underlying disease process, but not to portal hypertension overall. Liver function remains well preserved.

Entities:  

Mesh:

Year:  2010        PMID: 20075739     DOI: 10.1097/MEG.0b013e3283360021

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  10 in total

Review 1.  Nodular regenerative hyperplasia: evolving concepts on underdiagnosed cause of portal hypertension.

Authors:  Marek Hartleb; Krzysztof Gutkowski; Piotr Milkiewicz
Journal:  World J Gastroenterol       Date:  2011-03-21       Impact factor: 5.742

Review 2.  Human immunodeficiency virus and nodular regenerative hyperplasia of liver: A systematic review.

Authors:  Archita Sood; Mariana Castrejón; Sammy Saab
Journal:  World J Hepatol       Date:  2014-01-27

Review 3.  Benign liver tumors in pediatric patients - Review with emphasis on imaging features.

Authors:  Liliana Chiorean; Xin-Wu Cui; Andrea Tannapfel; Doris Franke; Martin Stenzel; Wojciech Kosiak; Dagmar Schreiber-Dietrich; Jörg Jüngert; Jian-Min Chang; Christoph F Dietrich
Journal:  World J Gastroenterol       Date:  2015-07-28       Impact factor: 5.742

4.  Aetio-pathogenesis and the management of spontaneous liver bleeding in the West: a 16-year single-centre experience.

Authors:  Narendra Battula; Dimitrios Tsapralis; Arjun Takhar; Chris Coldham; David Mayer; John Isaac; Paolo Muiesan; Robert P Sutcliffe; Ravi Marudanayagam; Darius F Mirza; Simon R Bramhall
Journal:  HPB (Oxford)       Date:  2012-04-09       Impact factor: 3.647

5.  Diagnosing Nodular Regenerative Hyperplasia of the Liver Is Thwarted by Low Interobserver Agreement.

Authors:  Bindia Jharap; Dirk P van Asseldonk; Nanne K H de Boer; Pierre Bedossa; Joachim Diebold; A Mieke Jonker; Emmanuelle Leteurtre; Joanne Verheij; Dominique Wendum; Fritz Wrba; Pieter E Zondervan; Jean-Frédéric Colombel; Walter Reinisch; Chris J J Mulder; Elisabeth Bloemena; Adriaan A van Bodegraven
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

6.  Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study.

Authors:  Tomas Koller; Martina Galambosova; Simona Filakovska; Michaela Kubincova; Tibor Hlavaty; Jozef Toth; Anna Krajcovicova; Juraj Payer
Journal:  World J Gastroenterol       Date:  2017-06-14       Impact factor: 5.742

7.  Fatal liver mass rupture in a common-variable-immunodeficiency patient with probable nodular regenerating hyperplasia.

Authors:  Mongkhon Sompornrattanaphan; Ranista Tongdee; Chamard Wongsa; Anupop Jitmuang; Torpong Thongngarm
Journal:  Allergy Asthma Clin Immunol       Date:  2022-01-07       Impact factor: 3.406

Review 8.  Heterogeneity of Liver Disease in Common Variable Immunodeficiency Disorders.

Authors:  Antonio Pecoraro; Ludovica Crescenzi; Gilda Varricchi; Giancarlo Marone; Giuseppe Spadaro
Journal:  Front Immunol       Date:  2020-02-28       Impact factor: 7.561

9.  Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom.

Authors:  Ahmed B Bayoumy; Elsa L S A van Liere; Melek Simsek; Ben Warner; Aathavan Loganayagam; Jeremy D Sanderson; Simon Anderson; Jonathan Nolan; Nanne K de Boer; Chris J J Mulder; Azhar Ansari
Journal:  BMC Gastroenterol       Date:  2020-09-11       Impact factor: 3.067

Review 10.  Liver manifestations and complications in inflammatory bowel disease: A review.

Authors:  Rui Gaspar; Catarina Castelo Branco; Guilherme Macedo
Journal:  World J Hepatol       Date:  2021-12-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.